Eicosanoid signaling pathway

The **Eicosanoid signaling pathway** is not a single molecule or receptor but rather a complex network of biochemical reactions responsible for the production and action of eicosanoids—bioactive lipid mediators derived from 20-carbon polyunsaturated fatty acids such as arachidonic acid. This pathway involves several key enzyme families, including cyclooxygenases (COX), lipoxygenases (LOX), and cytochrome P450 enzymes, which generate various classes of eicosanoids such as prostaglandins, thromboxanes, leukotrienes, lipoxins, and specialized pro-resolving mediators. These molecules play critical roles in regulating inflammation, immune responses, vascular tone, pain perception, fever induction, cell growth regulation, blood pressure control, and tissue homeostasis. Dysregulation or overproduction within this pathway is implicated in numerous diseases including inflammatory disorders (such as asthma), cardiovascular disease, cancer progression via modulation of the tumor microenvironment and immune evasion mechanisms. Drugs targeting this pathway include NSAIDs that inhibit COX enzymes to reduce pro-inflammatory prostaglandins; selective COX inhibitors; and leukotriene receptor antagonists used in asthma therapy. Monitoring specific eicosanoids can serve as biomarkers for disease activity or therapeutic efficacy. However—since "Eicosanoid signaling pathway" refers to an entire network rather than a discrete molecular target—it is not considered a direct therapeutic target itself but encompasses multiple druggable nodes within its cascade. [1][2][5][6][7]

Other names

Eicosanoid pathwayArachidonic acid cascadeEicosanoid biosynthetic pathway

Inhibition of cyclooxygenase enzymes to reduce prostaglandin synthesis; Blockade of leukotriene receptors to prevent leukotriene-mediated inflammation